Clinical Research Directory
Browse clinical research sites, groups, and studies.
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
Sponsor: Lund University Hospital
Summary
In this clinical trial, patients with gastric and gastroesophageal junction adenocarcinoma will be included. Treatment with curative intent will be given with chemotherapy for 4 cycles with fluorouracil, oxaliplatin and irinotecan preoperatively followed by surgery, and then additionally 4 cycles of the same chemotherapy postoperatively. The standard treatment today is preoperative treatment with fluorouracil and oxaliplatin pre-and postoperatively. The rationale for this trial is, that the addition of irinotecan might improve treatments results.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2018-12-14
Completion Date
2026-11-30
Last Updated
2025-09-10
Healthy Volunteers
No
Interventions
Fluorouracil
Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Oxaliplatin
Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Irinotecan
Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Locations (4)
Oslo University Hospital, Ullevål Hospital
Oslo, Norway
Lund University Hospital
Lund, Sweden
Karolinska University Hospital
Stockholm, Sweden
Centrallasarettet i Växjö
Vaxjo, Sweden